Inovio Investors Face April 7 Deadline in Securities Class Action Over Alleged Misstatements

Rosen Law Firm, a globally respected securities litigation firm, is urgently alerting investors in Inovio Pharmaceuticals Inc. ($INO) that they must act before April 7, 2026 to preserve their right to participate in an ongoing securities class action lawsuit. The deadline applies to investors who purchased Inovio securities during a critical 27-month window from October 10, 2023 through December 26, 2025, a period that saw significant market volatility in the biopharmaceutical sector and evolving regulatory scrutiny of early-stage drug developers.

The lawsuit centers on allegations that Inovio made materially false and misleading statements to investors regarding fundamental operational and clinical matters. Specifically, the litigation contends that the company misrepresented the severity of manufacturing deficiencies in its CELLECTRA device, a key delivery mechanism for its DNA-based vaccine candidates. Additionally, plaintiffs allege that Inovio substantially overstated the regulatory prospects for its lead candidate INO-3107 and exaggerated the likelihood of submitting a regulatory filing to the FDA, misleading shareholders about the company's pathway to commercialization.

The Core Allegations and Timeline

The securities class action targeting Inovio Pharmaceuticals focuses on disclosures made during a period when the biopharmaceutical company's stock performance and investor confidence were particularly sensitive to regulatory and manufacturing news. The allegations touch on three critical business pillars:

• CELLECTRA Device Manufacturing: Claims that the company downplayed or failed to adequately disclose deficiencies in the manufacturing process or quality control of its proprietary CELLECTRA electroporation device, which is essential to delivering its therapeutic candidates
• INO-3107 Regulatory Prospects: Allegations that Inovio misrepresented the regulatory pathway and FDA submission likelihood for INO-3107, potentially inflating investor expectations about near-term milestones
• Timeline Misrepresentation: Contentions that the company provided misleading guidance on when regulatory submissions might occur, affecting investment decisions

The 27-month window from October 2023 through December 2025 represents a period during which Inovio likely made multiple public statements, earnings calls, and regulatory filings that form the basis of the alleged misstatements. This extended timeline suggests a pattern of alleged misconduct rather than isolated statements.

Market Context and Investor Concerns

The allegations against Inovio Pharmaceuticals occur within the challenging landscape facing development-stage biopharmaceutical companies in 2023-2025. The sector faced headwinds including:

• Heightened Regulatory Scrutiny: The FDA has become increasingly stringent in its review of manufacturing facilities and quality assurance processes, particularly for novel delivery mechanisms like CELLECTRA
• Manufacturing Reality Checks: Multiple biotech companies faced unexpected manufacturing setbacks during the post-pandemic period, making operational transparency increasingly important to investors
• DNA Vaccine Market Evolution: The competitive landscape for DNA-based vaccines shifted significantly after the initial COVID-19 vaccine rollout, with investors reassessing timelines and clinical potential
• Capital Constraints: Smaller biotech firms faced tighter access to capital, making accurate disclosure of regulatory pathways critical to maintaining investor confidence

Inovio's focus on DNA immunotherapies for cancer and infectious diseases positions it in a crowded but potentially valuable market segment. However, the company's reliance on the CELLECTRA device as a differentiating technology means that any manufacturing issues could fundamentally undermine its competitive positioning and clinical development timeline. The alleged overstatement of regulatory prospects is particularly significant because development-stage biotech investors often base valuations heavily on the probability and timing of regulatory milestones.

Investor Implications and Why This Matters

For shareholders who purchased Inovio stock during the alleged misstatement period, the implications are substantial:

Potential Recovery: If the class action succeeds, eligible investors may recover portions of their investment losses through settlement or judgment proceeds. Given the scale of the alleged deception spanning 27 months, institutional investors and retail holders alike have material claims.

Stock Valuation Impact: The original misstatements likely inflated $INO's stock price during the class period. Investors who purchased at artificially elevated prices due to false regulatory or manufacturing claims have grounds for damages. The gap between promised regulatory progress and actual development status could represent substantial overvaluation.

Credibility and Forward Guidance: Successful litigation against Inovio would signal to the broader biopharmaceutical sector that regulators and courts take manufacturing disclosure seriously. This has ripple effects across companies with similar delivery platform technologies.

Critical Deadline: The April 7, 2026 deadline is not a suggestion but a hard cutoff for participation. Investors who miss this deadline generally lose the right to pursue individual claims or participate in class recovery, even if the case ultimately succeeds. Many jurisdictions do not permit late claims, making this deadline absolute.

For investors trying to determine whether they have standing in the class, Rosen Law Firm typically recommends reviewing:

• Purchase confirmations from the alleged class period (October 10, 2023 - December 26, 2025)
• Purchase price and quantity of $INO shares acquired
• Sale dates and prices, if shares were subsequently sold
• Documentation of losses incurred

What Happens Next

As the April 7, 2026 deadline approaches, affected Inovio investors should treat this as a time-sensitive matter requiring immediate consultation with legal counsel experienced in securities litigation. Rosen Law Firm and other firms representing the class will likely increase visibility as the deadline nears, but waiting until the last moment creates logistical risks.

The existence of this securities class action adds a new layer of financial risk for Inovio Pharmaceuticals beyond typical clinical and regulatory uncertainties. Settlement or judgment costs could materially impact the company's financial position and liquidity, particularly important for a development-stage company that may be burning cash while pursuing regulatory approval for INO-3107 and other candidates.

Investors who believe they were harmed by Inovio's alleged misstatements have a rapidly closing window to act. With the April 7, 2026 deadline marking the final opportunity to join the class action, securing experienced securities counsel should be an immediate priority for anyone who held $INO stock during the alleged misstatement period.